Handling Delayed or Missed Direct Oral Anticoagulant Doses: Model-informed Individual Remedial Dosing

Overview

Journal Blood Adv

Specialty Hematology

Date 2024 Sep 18

PMID 39293087

Authors

Xiao-Qin Liu

Zi-Ran Li

Chen-Yu Wang

Zheng Jiao

Affiliations

Soon will be listed here.

Abstract

Nonadherence to direct oral anticoagulant (DOAC) pharmacotherapy may increase the risk of thromboembolism or bleeding, and delayed or missed doses are the most common types of nonadherence. Current recommendations from regulatory agencies or guidelines regarding this issue lack evidence and fail to consider individual differences. This study aimed to develop individual remedial dosing strategies when the dose was delayed or missed for DOACs, including rivaroxaban, apixaban, edoxaban, and dabigatran etexilate. Remedial dosing regimens based on population pharmacokinetic (PK)-pharmacodynamic (PD) modeling and simulation strategies were developed to expeditiously restore drug concentration or PD biomarkers within the therapeutic range. Population PK-PD characteristics of DOACs were retrieved from previously published literature. The effects of factors that influence PK and PD parameters were assessed for their impact on remedial dosing regimens. A web-based dashboard was established with R-shiny to recommend remedial dosing regimens based on patient traits, dosing schedules, and delay duration. Addressing delayed or missed doses relies on the delay time and specific DOACs involved. Additionally, age, body weight, renal function, and polypharmacy may marginally affect remedial strategies. The proposed remedial dosing strategies surpass current recommendations, with less deviation time beyond the therapeutic range. The online dashboard offers quick and convenient solutions for addressing missed or delayed DOACs, enabling individualized remedial dosing strategies based on patient characteristics to mitigate the risks of bleeding and thrombosis.

References

Mueck W, Borris L, Dahl O, Haas S, Huisman M, Kakkar A . Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008; 100(3):453-61. View

Counterman E, Lawley S . Designing Drug Regimens that Mitigate Nonadherence. Bull Math Biol. 2021; 84(1):20. DOI: 10.1007/s11538-021-00976-3. View

Cuker A, Siegal D . Monitoring and reversal of direct oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2015; 2015:117-24. DOI: 10.1182/asheducation-2015.1.117. View

Counterman E, Lawley S . What should patients do if they miss a dose of medication? A theoretical approach. J Pharmacokinet Pharmacodyn. 2021; 48(6):873-892. DOI: 10.1007/s10928-021-09777-6. View

Yin Y, Liu X, Gu J, Li Z, Jiao Z . How to handle a delayed or missed dose of edoxaban in patients with non-valvular atrial fibrillation? A model-informed remedial strategy. Br J Clin Pharmacol. 2022; 89(7):2066-2075. DOI: 10.1111/bcp.15316. View

Toorop M, Lijfering W, Scheres L . The relationship between DOAC levels and clinical outcomes: The measures tell the tale. J Thromb Haemost. 2020; 18(12):3163-3168. PMC: 7756566. DOI: 10.1111/jth.15104. View

Cirincione B, Kowalski K, Nielsen J, Roy A, Thanneer N, Byon W . Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation. CPT Pharmacometrics Syst Pharmacol. 2018; 7(11):728-738. PMC: 6263664. DOI: 10.1002/psp4.12347. View

Liu X, Li Z, Wang C, Chen Y, Jiao Z . Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban. Pharmaceutics. 2023; 15(2). PMC: 9964148. DOI: 10.3390/pharmaceutics15020588. View

Eikelboom J, Quinlan D, Hirsh J, Connolly S, Weitz J . Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. JAMA Cardiol. 2017; 2(5):566-574. DOI: 10.1001/jamacardio.2017.0364. View

10.

Lip G, Nieuwlaat R, Pisters R, Lane D, Crijns H . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2009; 137(2):263-72. DOI: 10.1378/chest.09-1584. View

11.

MacCannell D, Berger Z, East L, Mercuri E, Kirschner J, Muntoni F . Population pharmacokinetics-based recommendations for a single delayed or missed dose of nusinersen. Neuromuscul Disord. 2021; 31(4):310-318. DOI: 10.1016/j.nmd.2021.02.014. View

12.

Li J, Zhang R, Yang G, Cai Q, Lang Y, Zhong F . Model-based precision dosing and remedial dosing recommendations for delayed or missed doses of isoniazid in Chinese patients with tuberculosis. Br J Clin Pharmacol. 2024; . DOI: 10.1111/bcp.16050. View

13.

Guo Y, Kotalczyk A, Imberti J, Wang Y, Lip G . Poor adherence to guideline-directed anticoagulation in elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. Eur Heart J Qual Care Clin Outcomes. 2021; 9(2):169-176. PMC: 9972510. DOI: 10.1093/ehjqcco/qcab054. View

14.

Clark E, Lawley S . Should patients skip late doses of medication? A pharmacokinetic perspective. J Pharmacokinet Pharmacodyn. 2022; 49(4):429-444. DOI: 10.1007/s10928-022-09812-0. View

15.

Clark E, Lawley S . How drug onset rate and duration of action affect drug forgiveness. J Pharmacokinet Pharmacodyn. 2024; 51(3):213-226. DOI: 10.1007/s10928-023-09897-1. View

16.

Park H, Jones B, Huang P, Kang H, Dietrich E, DeRemer C . Trajectories of Oral Anticoagulation Adherence and Associated Clinical Outcomes During Long-Term Anticoagulation Among Medicare Beneficiaries With Venous Thromboembolism. Ann Pharmacother. 2023; 57(12):1349-1360. DOI: 10.1177/10600280231155489. View

17.

Samuelson B, Cuker A . Measurement and reversal of the direct oral anticoagulants. Blood Rev. 2016; 31(1):77-84. PMC: 5296289. DOI: 10.1016/j.blre.2016.08.006. View

18.

Ueshima S, Hira D, Kimura Y, Fujii R, Tomitsuka C, Yamane T . Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. Br J Clin Pharmacol. 2018; 84(6):1301-1312. PMC: 5980466. DOI: 10.1111/bcp.13561. View

19.

Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler K . 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021; 23(10):1612-1676. PMC: 11636576. DOI: 10.1093/europace/euab065. View

20.

Dansirikul C, Lehr T, Liesenfeld K, Haertter S, Staab A . A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery. Thromb Haemost. 2012; 107(4):775-85. DOI: 10.1160/TH11-09-0656. View